Recently, several laboratory found that CaMK II as a downstream effector of TLR4 signaling (45, 83, 84) plays a key role in pathogenesis of cardiac hypertrophy under hyperlipidemia conditions. The gene discussed is CAMK2G; the disease is cardiac hypertrophy.